ILMN (Illumina) Retained Earnings : $-1,242 Mil (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Illumina Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Illumina's retained earnings for the quarter that ended in Dec. 2024 was $-1,242 Mil.

Illumina's quarterly retained earnings increased from Jun. 2024 ($-2,133 Mil) to Sep. 2024 ($-1,428 Mil) and increased from Sep. 2024 ($-1,428 Mil) to Dec. 2024 ($-1,242 Mil).

Illumina's annual retained earnings declined from Dec. 2022 ($1,142 Mil) to Dec. 2023 ($-19 Mil) and declined from Dec. 2023 ($-19 Mil) to Dec. 2024 ($-1,242 Mil).

Illumina Retained Earnings Historical Data

The historical data trend for Illumina's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Retained Earnings Chart

Illumina Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

4,723.00

5,485.00

1,142.00

-19.00

-1,242.00

Illumina Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Retained Earnings	Get a 7-Day Free Trial															-19.00	-145.00	-2,133.00	-1,428.00	-1,242.00

Illumina Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Illumina (NAS:ILMN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Illumina Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (NAS:ILMN) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

ILMN:Mexico 1ILMN:Italy 0J8Z:UK ILU:Germany ILU:Germany ILU:Germany I1LM34:Brazil ILMN:Austria

Address

5200 Illumina Way, San Diego, CA, USA, 92122

Website

https://www.illumina.com

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Executives

Jacob Thaysen	director, officer: Chief Executive Officer	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Aimee L Hoyt	officer: SVP, Chief People Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Susan H Tousi	officer: SVP Product Development	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Steven Barnard	officer: SVP, Chief Technology Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott B. Ullem	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Stephen P Macmillan	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Andrew Teno	director	C/O FIR TREE INC., 55 WEST 46TH STREET, 29TH FLOOR, NEW YORK NY 10036
Alexander Aravanis	officer: SVP, Chief Technology Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott D Ericksen	officer: VP, Chief Accounting Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Charles Dadswell	officer: Sr VP & General Counsel	5200 ILLUMINA WAY, SAN DIEGO CA 92122
John Edward Frank	officer: Chief Public Affairs Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Phillip G. Febbo	officer: SVP Chief Medical Officer	C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carissa Rollins	officer: SVP, Chief Information Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kevin Carl Pegels	officer: Chief of Global Operations	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jay T Flatley	officer: President & CEO	9885 TOWNE CENTRE DR, SAN DIEGO CA 92121